Complement-Mediated ADCP as a Distinct Cytotoxic Pathway for Monoclonal Antibodies

13 Apr 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

IntroductionMacrophage phagocytosis is a major cytotoxic mechanism for therapeutic monoclonal antibodies (mAbs) that opsonize target cells. This antibody-dependent cellular phagocytosis (ADCP) can occur via the Fcγ or complement pathways, but the relative contribution of these pathways to mAb-mediated cell clearance is not known. Here, we analyzed the kinetics, functional cooperation, and phagocytic capacities of Fcγ receptor-dependent and complement-dependent ADCP, separately and concomitantly, in primary macrophages challenged with mAb-opsonized lymphocytes.
Methods. Using quantitative live-cell imaging of primary mouse macrophages, genetic disruption of Fcγ receptor signaling, and controlled modulation of complement activity, we directly compared the kinetics, capacity, and exhaustion behavior of ADCP via the Fcγ (fADCP) and complement (cADCP) pathways. ResultscADCP operates as a mechanistically independent phagocytic pathway with distinct temporal dynamics.
Relative to fADCP, cADCP exhibits delayed onset but substantially greater cumulative target clearance. When both pathways are engaged simultaneously, their effects on target removal are additive, indicating functional non-redundancy. Notably, macrophages rendered refractory to further phagocytosis following fADCP retain full capacity for cADCP, demonstrating that complement receptor–mediated engulfment can bypass Fcγ receptor–associated hypophagia.

The study investigates how macrophages clear antibody-opsonized targets via two distinct ADCP pathways: Fcγ receptor–dependent (fADCP) and complement-dependent (cADCP) phagocytosis.
It aims to delineate the kinetics, capacity, and exhaustion behavior of these pathways, both separately and in combination, using primary mouse macrophages and controlled experimental modulation.

Approach combines quantitative live-cell imaging with genetic disruption of Fcγ receptor signaling and deliberate modulation of complement activity.
Direct comparisons are made between fADCP and cADCP in terms of onset timing, total clearance, and exhaustion under varying target burdens.

cADCP operates as a mechanistically independent phagocytic route with distinct temporal dynamics from fADCP.
Relative to fADCP, cADCP shows a slower initiation but achieves substantially greater cumulative target clearance over time.
When both pathways are engaged, their effects on target removal are additive, indicating non-redundant, complementary functionality.

Macrophages exhausted from phagocytosis via fADCP (hypophagia) can still execute cADCP, demonstrating that complement receptor–mediated engulfment can bypass Fcγ receptor–driven limitations.
Despite higher capacity, cADCP is not unlimited; increasing target burden leads to a dose-dependent state of complement-associated phagocytic exhaustion.
This exhaustion presents a kinetic profile that is distinct from fADCP-induced hypophagia and is largely reversible within 24 hours.

The literature disproportionately emphasizes Fcγ receptor–mediated pathways, with less attention to complement activation in ADCP.
The findings position complement-mediated ADCP as a quantitatively powerful mechanism contributing to overall mAb cytotoxicity against opsonized targets.
The study proposes a functional framework for how Fcγ and complement pathways differentially shape macrophage cytotoxic capacity and identifies effector exhaustion as a shared, but pathway-specific, constraint on sustained antibody-mediated clearance.

The work is conducted in murine primary macrophages; translational relevance to human systems requires validation.
Quantitative thresholds for exhaustion, reversibility timelines beyond 24 hours, and real-world applicability across mAb classes remain to be defined.

The results suggest therapeutic strategies could leverage both ADCP pathways to maximize cytotoxic efficacy while recognizing and potentially mitigating pathway-specific exhaustion.
The concept of complementary, finite cytotoxic capacity informs design considerations for durable antibody responses.